Population-Based Incidence of Ocular Neovascularization Following Central Retinal Artery Occlusion in Olmsted County, Minnesota.
central retinal artery occlusion
neovascular glaucoma
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
07
2021
accepted:
12
08
2021
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
31
8
2021
Statut:
epublish
Résumé
To determine the population-based incidence of ocular neovascularization (NV) following central retinal artery occlusion (CRAO) and systemic risk factors associated with its development. Diagnosis of CRAO between January 1, 1976, and September 9, 2016, was identified using the Rochester Epidemiology Project, a medical records linkage system for all medical care provided to residents of Olmsted County, Minnesota. Records were reviewed to confirm the diagnosis of CRAO, and data were collected on ocular NV and associated systemic diseases. There were 89 patients with CRAO. Subsequent ocular neovascularization developed in 14 (16%) patients. Neovascularization of the iris (NVI) was present in 9/14 (64%) of these patients, neovascularization of the angle (NVA) in 10/14 (71%), neovascularization of the disc (NVD) in 2/14 (14%), and neovascularization elsewhere (NVE) in 1/14 (7%). Of these 14 patients with NV, 9 (64%) developed neovascular glaucoma (NVG). The mean time from CRAO diagnosis to NV was 82 days (range 22 to 268 days). Excluding the patients with proliferative diabetic retinopathy or CRAO caused by CRVO, the mean time to NV diagnosis was 80 days and the shortest time to NV diagnosis was 22 days. Diabetes mellitus was present in 64% of those with NV compared to 23% of those without NV (P = 0.003). The population-based incidence of ocular neovascularization following CRAO is 16% and developed within 2 months in half the cohort. Patients with diabetes mellitus are at increased risk for NV complications.
Identifiants
pubmed: 34456558
doi: 10.2147/OPTH.S327704
pii: 327704
pmc: PMC8387312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3531-3537Informations de copyright
© 2021 Tanke et al.
Déclaration de conflit d'intérêts
Dr Timothy W Olsen reports personal fees from American Academy of Ophthalmology; Secretary for Quality of Care, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
Life Sci. 2013 Jun 13;92(22):1037-45
pubmed: 23603139
Int Ophthalmol. 1993 Feb;17(1):9-17
pubmed: 7686140
Ophthalmology. 1983 May;90(5):488-506
pubmed: 6192376
Am J Ophthalmol. 2011 Nov;152(5):820-3.e2
pubmed: 21794842
Korean J Ophthalmol. 2016 Oct;30(5):352-359
pubmed: 27729755
Mayo Clin Proc. 1996 Mar;71(3):266-74
pubmed: 8594285
Arch Ophthalmol. 1991 Mar;109(3):339-42
pubmed: 1706177
J Ophthalmol. 2019 Oct 9;2019:7202731
pubmed: 31687201
Eur J Ophthalmol. 2010 Nov-Dec;20(6):1042-6
pubmed: 20544682
Prog Retin Eye Res. 2005 Jul;24(4):493-519
pubmed: 15845346
Eye (Lond). 2013 Jun;27(6):688-97
pubmed: 23470793
Clin Ophthalmol. 2015 Jun 05;9:995-1000
pubmed: 26089631
Surv Ophthalmol. 2007 Jan;52 Suppl 1:S3-19
pubmed: 17240254